secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2026-08-06T20:11:52+00:00
Accession:  0001193125-26-338022
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed
--------------------------------------------------------------------------------

- Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.
- Net loss $96.3M ($0.77/share) vs $9.4M loss ($0.10/share) in Q2 2025.
- Adjusted EBITDA loss $34.4M vs $3.6M loss; operating loss $51.0M vs $12.6M.
- FY 2026 revenue guidance cut to $179M-$215M (62-68% decline) from prior 45-52% decline.
- Cash $46.8M, no debt; CEO cites slower-than-expected market recovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/0001193125-26-338022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/orgo-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer